| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3495 | MK-0952 | 934995-87-6 | MK-0952 is a novel, potent and selective PDE4 inhibitor with the potential for the treatment of long-term memory loss and mild cognitive impairment. |
|
V4294 | MK-3328 | 1201323-97-8 | MK-3328 is a novel and potentcandidate PET ligand for the clinical assessment of β-amyloid plaque load. |
|
V4327 | MK-6913 | 1398510-92-3 | MK-6913 (Tetrahydrofluoroene 52) is a tetrahydrofluorene analogue. |
|
V4289 | MK-8318 | 1416581-40-2 | MK-8318 is a novel, potent and selectivetricyclic tetrahydroquinoline analog that acts as a CRTh2 receptorantagonist with a Kiof 5.0 nM. |
|
V4359 | MK-996 | 157263-00-8 | MK-996 is a novel, potent, orally bioactive, highly selective, nonpeptide angiotensin II (AII) receptor antagonist with anti-hypertensive activity. |
|
V3572 | MS4077 | 2230077-10-6 | MS4077 is a potent PROTACdegrader of anaplastic lymphoma kinase (ALK)with aKdof 37 nM for binding affinity to ALK. |
|
V3923 | NALDEMEDINE | 916072-89-4 | Naldemedine (formerly known as S-297,995; S297995;trade name: Symproic) is a potent, orally bioavailable peripherally active, and selective μ-opioid receptor antagonist developed by Shionogi and has been approved in 2017 for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. |
|
V3666 | Napsagatran | 159668-20-9 | Napsagatran hydrate is a novel and specificinhibitor of extrinsic and intrinsic thrombin generation which inhibits clot-bound and free (fluid-phase) thrombin. |
|
V4383 | OBINUTUZUMAB | 949142-50-1 | Obinutuzumab (also called afutuzumab until 2009, originally GA101) is a novel glycoengineered and humanized Type II CD20 monoclonal antibody approved for treating non-Hodgkin lymphoma. |
|
V2238 | OPC-167832 | 1883747-71-4 | OPC-167832 (OPC167832) is a novel carbostyril derivative developed by Otsuka with potent antituberculosis activity, acting as a DprE1 (decaprenylphosphoryl-β-d-ribose 2′-oxidase) Inhibitor. |
|
V2468 | Palmitoyl Tripeptide-1 | 1628252-62-9 | Palmitoyl tripeptide-1 is a fatty acid-modified peptide. |
|
V3519 | Peliglitazar | 331744-64-0 | Peliglitazar is a novel dual α/γ PPAR (peroxisome proliferator-activated receptor) activator. |
|
V4370 | PEMBROLIZUMAB (Keytruda) | 1374853-91-4 | Pembrolizumab (formerly known as MK-3475 and lambrolizumab, trade name Keytruda) is a humanized antibody and PD-1/PD-L1 inhibitou used in cancer immunotherapy. |
|
V2127 | PF-02575799 | 863491-70-7 | PF-02575799 is a novel and potent microsomal triglyceride transfer protein (MTP)inhibitor with anIC50of 0.77±0.29 nM. |
|
V2119 | PF-06737007 | 1863905-38-7 | PF-06737007 (PF06737007) is a novel, potent, selective, peripherally restricted, efficacious, and well-toleratedpan-Trkinhibitor withanti-hyperalgesic activity. |
|
V2136 | PF-2771 | PF-2771 is a novel, potent and selective inhibitor of centromere protein E (CENP-E) with anticancer activity. | |
|
V3888 | Plazomicin (ACHN490) | 1154757-24-0 | Plazomicin (ACHN490; ACHN-490;Trade name:Zemdri) is a next-generation aminoglycoside antibacterial derived from sisomicin by appending a hydroxy-aminobutyric acid (HABA) substituent at position 1 and a hydroxyethyl substituent at position 6'. |
|
V4071 | PRL-8-53 | 51352-87-5 | PRL-8-53 is a nootropic research chemical derived from benzoic acid and phenylmethylamine (Benzylamine) that has been shown to act as a hypermnesic drug in humans; it was first synthesized by medical chemistry professor Nikolaus Hansl at Creighton University in the 1970s as part of his work on amino ethyl meta benzoic acid esters. |
|
V3949 | Ret-IN-1 | 2222755-14-6 | Ret-IN-1, a Selpercatinib analog, is a novel, potent, orally bioavailable and selective aRET kinaseinhibitor with anticancer activity. |
|
V4398 | RISLENEMDAZ | 808732-98-1 | Rislenemdaz (also known as MK-065; CERC-301) is a novel, potent, orally bioavailable and selectiveantagonist of the N-methyl-D-aspartate (NMDA) receptor subunit 2B(GluN2B) withKiandIC50of 8.1 nM and 3.6 nM, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
